The scientific value of currently studied outcomes with abuse-deterrent opioid formulations, and whether new or different outcomes are needed, will be up for discussion at a US FDA meeting on methods for assessing the real-world effects of such products.
The agency will hold a public workshop July 10-11 on data and methods for evaluating the postmarketing impact of opioids...




